Russell Investments Group, Ltd. Adc Therapeutics Sa Transaction History
Russell Investments Group, Ltd.
- $69.8 Billion
- Q4 2024
A detailed history of Russell Investments Group, Ltd. transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 16,794 shares of ADCT stock, worth $26,870. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,794
Previous 7,546
122.55%
Holding current value
$26,870
Previous $23,000
43.48%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ADCT
# of Institutions
85Shares Held
53.5MCall Options Held
28KPut Options Held
60.4K-
Redmile Group, LLC San Francisco, CA15.7MShares$25.1 Million2.44% of portfolio
-
Prosight Management, LP Dallas, TX9.52MShares$15.2 Million5.62% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.97MShares$9.55 Million0.32% of portfolio
-
Morgan Stanley New York, NY3.96MShares$6.33 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$5.69 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $124M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...